The conversation discusses hair loss treatments, including finasteride, microneedling, minoxidil, and PTD-DBM. The user has not noticed significant regrowth and is considering cost-effective options like valproic acid.
User ronopibf discusses Fagron TrichoTest, a genetic test for hair loss, and seeks opinions on its effectiveness. Some users support the service, while others call it a scam, with prices ranging from $200-$500.
A new hair loss treatment called TDM-105795 is discussed as a potential replacement or add-on to Minoxidil. Users express hope for new effective treatments.
Hair loss treatments, specifically 5AR inhibitors, can impact neurosteroids and sexual health. The effects of topical fin/dut on tissue-specific DHT levels are unclear.
NMN shows promise in promoting hair growth by reducing oxidative stress and weakening androgens. It may be a beneficial addition to hair loss treatments like Minoxidil and Finasteride.
The conversation discusses hair loss treatments, specifically mentioning Minoxidil, finasteride, RU58841, and Xeljanz. The user inquires about Xeljanz and shares a link suggesting it may help with hair loss.
A 27-year-old male shared his hair regrowth progress after 100 days using 5% Minoxidil twice daily, 1.25mg Finasteride daily, and weekly microneedling. He noticed improvements and hopes to avoid a future hair transplant.
A user shared progress pictures showing significant hair regrowth after using 1mg finasteride and weekly microneedling for about 2.5 to 3 months. The user reported no side effects and maintained good health and mood.
HMI 115 did not work as expected for hair regrowth in humans, unlike in macaque monkeys. There is anticipation for further research on prolactin's role in hair loss, with expectations that pharmaceutical companies will likely solve this before universities.
GT20029 shows promising results for hair loss treatment, with potential approval in China by 2026 or 2027, but U.S. approval may take longer. It could serve as an alternative to finasteride, with a potentially better side effect profile.
The conclusion of the conversation is that CosmeRna may not be an effective treatment for hair loss compared to topical minoxidil 2%. It is suggested to wait for more reviews before purchasing it.
A user shared their hair transformation over four months using daily 2.5mg oral minoxidil, every other day 1mg oral finasteride, weekly dermastamping, and daily scalp massages, with plans for a hair transplant. Another user suggested continuing the medication for a year before considering a transplant.
Injectable GHK-CU and BPC157 were discussed for hair loss, but users did not notice significant hair changes. BPC157 was noted to help with shoulder issues.
Tazarotene may be more effective than tretinoin when combined with topical minoxidil for hair loss due to its selective binding to RAR-beta and gamma, though it can cause irritation. Tazarotene's potency can lead to indirect inflammatory reactions despite potentially causing less irritation than tretinoin.
The conversation is about the potential of the RCH-01/Replicel hair loss treatment and its lack of updates since 2013, with the user expressing hope for its success and considering using Minoxidil, finasteride, and dermarolling in the meantime. Other treatments mentioned as promising are Breezula and Tsuji.
A user is seeking a new source for RU58841 in the EU after their previous supplier stopped selling it. They mention considering Anagen, Actifolic, Minoxidilmax, and rudirect, and are using a treatment mixing RU58841 with Stemoxydine and Alfatradiol.
A user is seeking a new source for RU58841 in the EU after their previous supplier stopped selling it. They mention considering Anagen, Actifolic, Minoxidilmax, and rudirect, and are using a treatment mixing RU58841 with Stemoxydine and Alfatradiol.
RU58841 caused severe side effects like heart palpitations and shortness of breath, leading the user to stop using it. Minoxidil and finasteride were effective without side effects, while RU58841's safety and effectiveness remain uncertain.
RU58841 is preferred over finasteride for blocking DHT on the scalp, especially for those with aggressive MPB. Creatine is associated with increased hair shedding, even when using RU58841.
User shared 8-month hair loss treatment progress using topical fin/min, topical dut, mk677, RU, and microneedling. They experienced watery semen as a side effect but saw significant improvement in hair growth.
The post discusses the potential of GT20029 in treating hair loss, questioning if it will replace finasteride or be used alongside existing treatments. A reply indicates that its role is still uncertain.
A user shared progress pictures showing improved hair fullness after 75 days using 2.5mg oral minoxidil daily, 1mg oral finasteride every other day, a 1.5mm dermastamp weekly, and daily scalp massages. They report seeing early positive results.
The conversation discusses RU58841, a compound for hair loss treatment, which was found to be effective in a 6-month trial but was not pursued due to financial issues or marketability concerns, not safety. Some users are considering crowdfunding to release the research data, while others discuss personal experiences and safety concerns with RU58841.
The conversation discusses using PGE2 as a hair growth stimulant, comparing it to minoxidil, and considering the addition of Setipiprant. Concerns about side effects like skin damage and cost are also mentioned.
A new hair loss treatment involving Keratin Microsphere Gel is discussed, with skepticism and jokes about its effectiveness and comparisons to other treatments. Users are doubtful and make light of the situation, referencing past disappointments and the study's focus on mice.
The conversation discusses whether gt20029 could cure complete baldness, mentioning verteporfin as a realistic treatment. Other treatments like Minoxidil, finasteride, and RU58841 are implied to be less promising.
The post discusses the completion of the HMI-115 Australian Phase 1 Trial for hair loss treatment. The user speculates about the potential early release of the trial results.